Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Evaluation of the hypothetical risk of sudden cardiac death in obstructive HCM patients treated with mavacamten using the HCM Risk-SCD score
Session:
Sessão de Posters 48 - Risco arrítmico, tomada de decisão e desfechos nas miocardiopatias
Speaker:
Mariana Rocha Morato Silveira Ramos
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
17. Myocardial Disease
Subtheme:
17.4 Myocardial Disease – Treatment
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Mariana Silveira Ramos; Rui Gomes; Rita Lima; Débora Correia; Sérgio Maltês; Tânia Laranjeira; Gonçalo Cunha; Carlos Aguiar; Bruno M. Rocha
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong>Background:</strong> Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of sudden cardiac death (SCD). Risk stratification may be performed using the HCM Risk-SCD score, which has been validated in cohorts of patients treated with first-line medical therapy (beta-blockers or calcium channel blockers). Mavacamten, a novel selective cardiac myosin inhibitor, has been shown to reduce left ventricular outflow tract obstruction (LVOTO) and to promote reverse remodeling. Its influence on the estimated HCM Risk-SCD score, which incorporates echocardiographic parameters that may change with therapy, remains unclear.</span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong>Objective:</strong> To assess hypothetical changes in the estimated HCM Risk-SCD score in patients with obstructive HCM treated with mavacamten.</span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong>Methods:</strong> We conducted a prospective observational study including all patients with HCM treated with mavacamten who had been on a stable dose for at least 3 months. Clinical data and transthoracic echocardiograms were reviewed to collect maximal wall thickness (MWT), left atrial diameter (LAD), and maximal LVOTO. The HCM Risk-SCD score was calculated using the ESC online tool. Comparisons were assessed using the Wilcoxon signed-rank test.</span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong>Results:</strong> Forty patients were included [58% male; median age 62 (61–71) years and follow-up 7 (3–12) months]. Echocardiographic parameters improved significantly in comparison to baseline, with reductions in maximal LVOTO [84 (68–129) vs. 5 (0–39) mmHg; p<0.001], MWT [18 (16–20) vs. 15 (14–18) mm; p<0.001], and LAD [43 (39–47) vs. 40 (36–44) mm; p=0.008]. Mavacamten was associated with a significant reduction in the HCM Risk-SCD score, decreasing from 2.4 (1.7–4.7) to 1.5 (1.1–2.6) %, corresponding to an absolute change of −0.9 (−2.0 to −0.5) % and a relative reduction of −40 (−52 to −26) % (p<0.001) (<strong><span style="color:#0070c0">central figure</span></strong>). At baseline, four patients had a high estimated 5-year SCD risk (>6%) – all of whom had an implantable cardioverter-defibrillator. During follow-up, three were reclassified in the low-risk category (<4%), while one remained in the high-risk group. No patient transitioned into a higher risk category after treatment. Per-patient decomposition of the HCM Risk-SCD reduction showed that most of the improvement was driven by changes in LVOTO (median −0.52%), with smaller contributions from MWT (−0.29%) and LAD (−0.08%).</span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong>Conclusion:</strong> Mavacamten was associated with a significant reduction in the estimated HCM Risk-SCD score. Whether this improvement translates into a true reduction in the 5-year SCD incidence remains uncertain. External validation in large multicenter cohorts with long-term follow-up is required to determine whether the decrease in the hypothetical risk corresponds to reduced mortality.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site